Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 May;41(5):1137–1139. doi: 10.1128/aac.41.5.1137

Interpretive criteria for testing susceptibility of staphylococci to mupirocin.

J E Finlay 1, L A Miller 1, J A Poupard 1
PMCID: PMC163864  PMID: 9145883

Abstract

To determine appropriate mupirocin susceptibility testing interpretive criteria, 177 staphylococci were tested by agar dilution, disk diffusion, and E test. E test was found to be a reliable method for determining susceptibility of staphylococci to mupirocin. The agar dilution and disk diffusion results were plotted on a scattergram, and error rates were calculated. No errors were found with susceptibility breakpoints of > or = 4 microg/ml (MIC) and > or = 14 mm (zone diameter).

Full Text

The Full Text of this article is available as a PDF (215.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barry A. L., Pfaller M. A., Fuchs P. C. Ramoplanin susceptibility testing criteria. J Clin Microbiol. 1993 Jul;31(7):1932–1935. doi: 10.1128/jcm.31.7.1932-1935.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Doebbeling B. N., Breneman D. L., Neu H. C., Aly R., Yangco B. G., Holley H. P., Jr, Marsh R. J., Pfaller M. A., McGowan J. E., Jr, Scully B. E. Elimination of Staphylococcus aureus nasal carriage in health care workers: analysis of six clinical trials with calcium mupirocin ointment. The Mupirocin Collaborative Study Group. Clin Infect Dis. 1993 Sep;17(3):466–474. doi: 10.1093/clinids/17.3.466. [DOI] [PubMed] [Google Scholar]
  3. Fuchs P. C., Jones R. N., Barry A. L. Interpretive criteria for disk diffusion susceptibility testing of mupirocin, a topical antibiotic. J Clin Microbiol. 1990 Mar;28(3):608–609. doi: 10.1128/jcm.28.3.608-609.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Hudson I. R. The efficacy of intranasal mupirocin in the prevention of staphylococcal infections: a review of recent experience. J Hosp Infect. 1994 Jun;27(2):81–98. doi: 10.1016/0195-6701(94)90001-9. [DOI] [PubMed] [Google Scholar]
  5. Metzler C. M., DeHaan R. M. Susceptibility tests of anaerobic bacteria: statistical and clinical considerations. J Infect Dis. 1974 Dec;130(6):588–594. doi: 10.1093/infdis/130.6.588. [DOI] [PubMed] [Google Scholar]
  6. Poupard J. A. Update on mupirocin resistance. J Chemother. 1995 Jul;7 (Suppl 3):71–74. [PubMed] [Google Scholar]
  7. Sutherland R., Boon R. J., Griffin K. E., Masters P. J., Slocombe B., White A. R. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrob Agents Chemother. 1985 Apr;27(4):495–498. doi: 10.1128/aac.27.4.495. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES